BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 18667446)

  • 1. Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling.
    Cao L; Petrusca DN; Satpathy M; Nakshatri H; Petrache I; Matei D
    Carcinogenesis; 2008 Oct; 29(10):1893-900. PubMed ID: 18667446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
    Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
    Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alkaloids from Stephania venosa as Chemo-Sensitizers in SKOV3 Ovarian Cancer Cells via Akt/NF-κB Signaling.
    Mon MT; Yodkeeree S; Punfa W; Pompimon W; Limtrakul P
    Chem Pharm Bull (Tokyo); 2018; 66(2):162-169. PubMed ID: 29386467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p62/SQSTM1 as an oncotarget mediates cisplatin resistance through activating RIP1-NF-κB pathway in human ovarian cancer cells.
    Yan XY; Zhang Y; Zhang JJ; Zhang LC; Liu YN; Wu Y; Xue YN; Lu SY; Su J; Sun LK
    Cancer Sci; 2017 Jul; 108(7):1405-1413. PubMed ID: 28498503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracellular tissue transglutaminase activates noncanonical NF-κB signaling and promotes metastasis in ovarian cancer.
    Yakubov B; Chelladurai B; Schmitt J; Emerson R; Turchi JJ; Matei D
    Neoplasia; 2013 Jun; 15(6):609-19. PubMed ID: 23730209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of expression of XIAP-associated factor 1 (XAF1) with clinicopathologic factors, overall survival, microvessel density and cisplatin-resistance in ovarian cancer.
    Wang Y; Mao H; Hao Q; Wang Y; Yang Y; Shen L; Huang S; Liu P
    Regul Pept; 2012 Oct; 178(1-3):36-42. PubMed ID: 22759793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue transglutaminase constitutively activates HIF-1α promoter and nuclear factor-κB via a non-canonical pathway.
    Kumar S; Mehta K
    PLoS One; 2012; 7(11):e49321. PubMed ID: 23185316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer.
    Miow QH; Tan TZ; Ye J; Lau JA; Yokomizo T; Thiery JP; Mori S
    Oncogene; 2015 Apr; 34(15):1899-907. PubMed ID: 24858042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FSTL1 increases cisplatin sensitivity in epithelial ovarian cancer cells by inhibition of NF-κB pathway.
    Liu YK; Jia YJ; Liu SH; Ma J
    Cancer Chemother Pharmacol; 2021 Mar; 87(3):405-414. PubMed ID: 33392640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.
    Asselin E; Mills GB; Tsang BK
    Cancer Res; 2001 Mar; 61(5):1862-8. PubMed ID: 11280739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway.
    Zhang C; Wang M; Shi C; Shi F; Pei C
    Biosci Trends; 2018 Jul; 12(3):309-316. PubMed ID: 29952351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of MTRR gene on apoptosis and autophagy pathways in multiresistant epithelial ovarian cancer].
    Chen J; Wang Q; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2016 Apr; 51(4):285-92. PubMed ID: 27116987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The inhibitory effect of doxycycline on cisplatin-sensitive and -resistant epithelial ovarian cancer.
    Wu W; Yu LH; Ma B; Xu MJ
    PLoS One; 2014; 9(3):e89841. PubMed ID: 24598933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caveolin-1 mediates chemoresistance in cisplatin-resistant ovarian cancer cells by targeting apoptosis through the Notch-1/Akt/NF-κB pathway.
    Zou W; Ma X; Hua W; Chen B; Cai G
    Oncol Rep; 2015 Dec; 34(6):3256-63. PubMed ID: 26503358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells.
    Chock KL; Allison JM; Shimizu Y; ElShamy WM
    Cancer Res; 2010 Nov; 70(21):8782-91. PubMed ID: 20940403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
    Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
    Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylation of transglutaminase 2 (TG2) at serine-216 has a role in TG2 mediated activation of nuclear factor-kappa B and in the downregulation of PTEN.
    Wang Y; Ande SR; Mishra S
    BMC Cancer; 2012 Jul; 12():277. PubMed ID: 22759359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Knockdown of Eag1 Expression by RNA Interference Increases Chemosensitivity to Cisplatin in Ovarian Cancer Cells.
    Hui C; Lan Z; Yue-li L; Li-lin H; Li-lin H
    Reprod Sci; 2015 Dec; 22(12):1618-26. PubMed ID: 26079730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PDCD6 additively cooperates with anti-cancer drugs through activation of NF-κB pathways.
    Park SH; Lee JH; Lee GB; Byun HJ; Kim BR; Park CY; Kim HB; Rho SB
    Cell Signal; 2012 Mar; 24(3):726-33. PubMed ID: 22142513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.
    Gao Y; Shan N; Zhao C; Wang Y; Xu F; Li J; Yu X; Gao L; Yi Z
    Int J Clin Exp Pathol; 2015; 8(5):4923-32. PubMed ID: 26191185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.